Fleischmann R, et al. - Through a post hoc analysis of 423 patients with active rheumatoid arthritis (RA) from RA-BEGIN who began a long-term extension, RA-BEYOND, and were evaluated up to 24 weeks, the researchers assessed the long-term efficiency and safety of maintaining baricitinib monotherapy in RA patients originally treated with baricitinib monotherapy or who changed from methotrexate (MTX) or the combination of baricitinib plus MTX to baricitinib monotherapy. As estimated by the Simplified Disease Activity Index, Clinical Disease Activity Index, and Health Assessment Questionnaire-Disability Index scores, patients with lower disease activity at RA-BEYOND baseline proceeded to do properly with baricitinib monotherapy. Post-addition of MTX, patients prescribed MTX had greater disease activity at the RA-BEYOND baseline and had better disease activity. Hence, exhibiting sustained or enhanced disease control, several patients reacted well to continued baricitinib monotherapy or to changing to baricitinib monotherapy from MTX monotherapy or baricitinib plus MTX. Further, a sustained or better disease control with the addition of MTX to baricitinib was recognized in the groups of patients who had more limited disease control on their original therapies.